Angionetics Overview
- Year Founded
-
2001

- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
2
Angionetics General Information
Description
Developer of biotechnology products for cardiac issues. The company is focused on the development and commercialization of novel DNA-based therapeutics designed to promote the heart's innate natural capacity to modulate the formation and growth of cardiac microvascular circulation to enhance blood flow in patients with a variety of ischemia-driven disease conditions and refractory angina and myocardial ischemia due to cardiac microvascular insufficiency (CMI), and other cardiovascular disease conditions.
Contact Information
- 11750 Sorrento Valley Road
- Suite 250
- San Diego, CA 92121
- United States
Angionetics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Angionetics Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Christopher Reinhard | Chief Executive Officer | ||
Lois Chandler Ph.D | Vice President of Product Development |
Angionetics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|